Skip to content
Walmsley's GSK gamble episode artwork

Dec 24, 2018 9 min

Walmsley's GSK gamble

from FT News in Focus

GlaxoSmithKline is combining its consumer health business with that of US rival Pfizer, paving the way for a separation of its core consumer and pharmaceuticals businesses within three years. Chief executive Emma Walmsley is betting the cash generated by the enlarged consumer unit will fund further investment in the pharmaceutical business ahead of the demerger. Matthew Vincent is joined by Sarah Neville and Arash Massoudi to discuss the merits of the deal and its implications for the health and pharmaceuticals markets. Contributors: Naomi Rovnick, FT Live reporter, Matthew Vincent, Lombard columnist, Sarah Neville, global pharmaceuticals editor and Arash Massoudi, corporate finance and deals editor. Producer: Sam Westran

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Walmsley's GSK gamble

0:00 9:06

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of FT News in Focus?

This episode is 9 minutes long.

When was this FT News in Focus episode published?

This episode was published on December 24, 2018.

Can I download this FT News in Focus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.